Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Retatrutide is the developmental designation for an investigational compound owned by Eli Lilly and Company
Abubaker AA, Vara D, Visconte C, Eggleston I, Torti M, Canobbio I, et al
Finkley MB, Appa Y, Bhandarkar S
It is a two-compound research protocol that pairs cagrilintide (an amylin analog that signals fullness through the hindbrain) with retatrutide (a triple GLP-1 / GIP / glucagon agonist)
The peptide promoted Schwann cell proliferation, enhanced axonal regrowth, and improved nerve conduction velocity recovery
US$ 20.06
US$ 27.54
US$ 23.72
US$ 26.62
US$ 22.26
US$ 27.51
US$ 27.70
US$ 26.66
US$ 23.74
US$ 25.06
US$ 24.52
